These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 27506682)

  • 1. Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras.
    Klein MB; Althoff KN; Jing Y; Lau B; Kitahata M; Lo Re V; Kirk GD; Hull M; Kim HN; Sebastiani G; Moodie EE; Silverberg MJ; Sterling TR; Thorne JE; Cescon A; Napravnik S; Eron J; Gill MJ; Justice A; Peters MG; Goedert JJ; Mayor A; Thio CL; Cachay ER; Moore R; ;
    Clin Infect Dis; 2016 Nov; 63(9):1160-1167. PubMed ID: 27506682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015.
    Sun J; Althoff KN; Jing Y; Horberg MA; Buchacz K; Gill MJ; Justice AC; Rabkin CS; Goedert JJ; Sigel K; Cachay E; Park L; Lim JK; Kim HN; Lo Re V; Moore R; Sterling T; Peters MG; Achenbach CJ; Silverberg M; Thorne JE; Mayor AM; Crane HM; Kitahata MM; Klein M; Kirk GD;
    JAMA Netw Open; 2021 Feb; 4(2):e2037512. PubMed ID: 33595662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver decompensation in HIV/Hepatitis B coinfection in the combination antiretroviral therapy era does not seem increased compared to hepatitis B mono-infection.
    Lieveld FI; Smit C; Richter C; van Erpecum KJ; Spanier BWM; Gisolf EH; Vrolijk JM; Siersema PD; Hoepelman AIM; Reiss P; Arends JE
    Liver Int; 2019 Mar; 39(3):470-483. PubMed ID: 30411848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon.
    Mbougua JB; Laurent C; Kouanfack C; Bourgeois A; Ciaffi L; Calmy A; Gwet H; Koulla-Shiro S; Ducos J; Mpoudi-Ngolé E; Molinari N; Delaporte E
    BMC Public Health; 2010 Mar; 10():105. PubMed ID: 20193053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinants of Liver Complications Among HIV/Hepatitis B Virus-Coinfected Patients.
    Lo Re V; Newcomb CW; Carbonari DM; Roy JA; Althoff KN; Kitahata MM; Reddy KR; Lim JK; Silverberg MJ; Mayor AM; Horberg MA; Cachay ER; Kirk GD; Hull M; Gill J; Sterling TR; Kostman JR; Peters MG; Moore RD; Klein MB; Kim HN;
    J Acquir Immune Defic Syndr; 2019 Sep; 82(1):71-80. PubMed ID: 31107304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. End-stage liver disease: prevalence, risk factors and clinical characteristics in a cohort of HIV-HCV coinfected Han Chinese.
    Deng L; Gui X; Xiong Y; Gao S; Yang R; Rong Y; Hu J; Yan Y
    Clin Res Hepatol Gastroenterol; 2012 Dec; 36(6):574-82. PubMed ID: 22481087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling the impact of early antiretroviral therapy for adults coinfected with HIV and hepatitis B or C in South Africa.
    Martin NK; Devine A; Eaton JW; Miners A; Hallett TB; Foster GR; Dore GJ; Easterbrook PJ; Legood R; Vickerman P
    AIDS; 2014 Jan; 28 Suppl 1():S35-46. PubMed ID: 24468945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study.
    Tedaldi E; Peters L; Neuhaus J; Puoti M; Rockstroh J; Klein MB; Dore GJ; Mocroft A; Soriano V; Clotet B; Lundgren JD;
    Clin Infect Dis; 2008 Dec; 47(11):1468-75. PubMed ID: 18959492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV.
    Limketkai BN; Mehta SH; Sutcliffe CG; Higgins YM; Torbenson MS; Brinkley SC; Moore RD; Thomas DL; Sulkowski MS
    JAMA; 2012 Jul; 308(4):370-8. PubMed ID: 22820790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects.
    De Luca A; Bugarini R; Lepri AC; Puoti M; Girardi E; Antinori A; Poggio A; Pagano G; Tositti G; Cadeo G; Macor A; Toti M; D'Arminio Monforte A;
    Arch Intern Med; 2002 Oct; 162(18):2125-32. PubMed ID: 12374521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seroprevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) among human immunodeficiency virus (HIV)-infected patients in an HBV endemic area in Brazil.
    da Silva CM; de Peder LD; Guelere AM; Horvath JD; Silva ES; Teixeira JJV; Bertolini DA
    PLoS One; 2018; 13(9):e0203272. PubMed ID: 30192795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes of liver transplantation in human immunodeficiency virus/hepatitis B virus coinfected patients in China.
    Tang J; Weng R; Fang T; Zhang K; Yan X; Jin X; Xie L; Zhao D
    BMC Infect Dis; 2024 Apr; 24(1):383. PubMed ID: 38589801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety profile of maraviroc in patients coinfected with HIV-1 and hepatitis B or C included in the maraviroc expanded access program.
    Lazzarin A; Than S; Valluri SR; Heera J; Mukwaya G
    HIV Clin Trials; 2012; 13(2):83-9. PubMed ID: 22510355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased risk of hip fracture associated with dually treated HIV/hepatitis B virus coinfection.
    Byrne DD; Newcomb CW; Carbonari DM; Nezamzadeh MS; Leidl KB; Herlim M; Yang YX; Hennessy S; Kostman JR; Leonard MB; Localio AR; Lo Re V
    J Viral Hepat; 2015 Nov; 22(11):936-47. PubMed ID: 25754215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination Antiretroviral Therapy Is Associated With Reduction in Liver Fibrosis Scores in HIV-1-Infected Subjects.
    Li Y; Xie J; Han Y; Wang H; Lv W; Guo F; Qiu Z; Li Y; Du S; Song X; Zhu T; Thio CL; Li T
    Medicine (Baltimore); 2016 Feb; 95(5):e2660. PubMed ID: 26844493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of HIV/hepatitis B virus/hepatitis C virus RNA+ triple infection in end-stage liver disease and all-cause mortality in Europe.
    Mocroft A; Geressu A; Beguelin C; Llibre JM; Lazarus JV; Tomazic J; Smidt J; Parczewski M; Brännström J; Sedlacek D; Degen O; van der Valk M; Paduta D; Flamholc L; Schmid P; Orkin C; Nielsen LN; Hoffmann C; Beniowski M; Oprea C; Begovac J; Peters L
    AIDS; 2023 Jan; 37(1):91-103. PubMed ID: 36476454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic safety and tolerability of raltegravir among HIV patients coinfected with hepatitis B and/or C.
    Hurt CB; Napravnik S; Moore RD; Eron JJ
    Antivir Ther; 2014; 19(4):415-22. PubMed ID: 24458137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact and management of hepatitis B and hepatitis C virus co-infection in HIV patients.
    Kumar R; Singla V; Kacharya Sk
    Trop Gastroenterol; 2008; 29(3):136-47. PubMed ID: 19115605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B viremia in HIV-coinfected individuals under antiretroviral therapy.
    Weissmann L; Picone CM; Gouvêa MSG; Ferreira PRA; Viana MSVB; Pinho JRR; Cassenote AJF; Segurado AC
    Braz J Infect Dis; 2019; 23(6):441-450. PubMed ID: 31715124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients.
    Kruse RL; Kramer JR; Tyson GL; Duan Z; Chen L; El-Serag HB; Kanwal F
    Hepatology; 2014 Dec; 60(6):1871-8. PubMed ID: 25065513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.